Mutations in the rhodopsin (RHO) gene are the predominant causes of autosomal dominant retinitis pigmentosa (adRP). Given the diverse gain-of-function mutations, therapeutic strategies targeting specific sequences face significant challenges. Here, we provide a universal approach to conquer this problem: we have devised a CRISPR-Cas12i-based, mutation-independent gene knockout and replacement compound therapy carried by a dual AAV2/8 system. In this study, we successfully delayed the progression of retinal degeneration in the classic mouse disease model RhoP23H, and also RhoP347S, a new native mouse mutation model we developed. Our research expands the horizon of potential options for future treatments of RHO-mediated adRP.
Get full access to this article
View all access options for this article.
References
1.
VerbakelSK, van HuetRAC, BoonCJF, et al.Non-syndromic retinitis pigmentosa. Prog Retin Eye Res, 2018; 66:157–186.
2.
DiasMF, JooK, KempJA, et al.Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res, 2018; 63:107–131.
JacobsonSG, KempCM, SungCH, et al.Retinal function and rhodopsin levels in autosomal dominant retinitis pigmentosa with rhodopsin mutations. Am J Ophthalmol, 1991; 112(3):256–271.
6.
AthanasiouD, AguilaM, BellinghamJ, et al.The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res, 2018; 62:1–23.
7.
PalczewskiK. G protein-coupled receptor rhodopsin. Annu Rev Biochem, 2006; 75:743–767.
8.
NathansJ, HognessDS. Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc Natl Acad Sci U S A, 1984; 81(15):4851–4855.
9.
NathansJ, PiantanidaTP, EddyRL, et al.Molecular genetics of inherited variation in human color vision. Science, 1986; 232(4747):203–210.
10.
LiT, SnyderWK, OlssonJE, et al.Transgenic mice carrying the dominant rhodopsin mutation P347S: Evidence for defective vectorial transport of rhodopsin to the outer segments. Proc Natl Acad Sci U S A, 1996; 93(24):14176–14181.
11.
OlssonJE, GordonJW, PawlykBS, et al.Transgenic mice with a rhodopsin mutation (Pro23His): A mouse model of autosomal dominant retinitis pigmentosa. Neuron, 1992; 9(5):815–830.
12.
MachidaS, KondoM, JamisonJA, et al.P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. Invest Ophthalmol Vis Sci, 2000; 41(10):3200–3209.
13.
YanZ, YaoY, LiL, et al.Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice. Mol Ther Nucleic Acids, 2023; 33:750–761.
14.
LaVailMM, YasumuraD, MatthesMT, et al.Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proc Natl Acad Sci U S A, 2000; 97(21):11488–11493.
15.
GiannelliSG, LuoniM, CastoldiV, et al.Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum Mol Genet, 2018; 27(5):761–779.
16.
LiP, KleinstiverBP, LeonMY, et al.Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for Rhodopsin-associated dominant retinitis pigmentosa. CRISPR J, 2018; 1(1):55–64.
17.
CideciyanAV, SudharsanR, DufourVL, et al.Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proc Natl Acad Sci U S A, 2018; 115(36):E8547–E8556.
18.
OrlansHO, McClementsME, BarnardAR, et al.Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. Nat Commun, 2021; 12(1):4934.
19.
TsaiYT, WuWH, LeeTT, et al.CRISPR-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa. Ophthalmology, 2018. 125(9):1421–1430.
20.
Millington-WardS, ChaddertonN, O'ReillyM, et al.Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther, 2019; 19(4):642–649.
21.
Millington-WardS. Strategems in vitro for gene therapies directed to dominant mutations. Hum Mol Genet, 1997; 6(9):1415–1426.
22.
WuWH, TsaiYT, HuangIW, et al.CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa. Mol Ther, 2022; 30(4):1407–1420.
23.
PacesaM, LinCH, CléryA, et al.Structural basis for Cas9 off-target activity. Cell, 2022; 185(22):4067–4081.e21.
24.
ChenY, HuY, WangX, et al.Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing. Innovation (Camb), 2022; 3(4):100264.
25.
FeodorovaY, KochM, BultmanS, et al.Quick and reliable method for retina dissociation and separation of rod photoreceptor perikarya from adult mice. MethodsX, 2015; 2:39–46.
26.
LiW, TengF, LiT, et al.Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol, 2013; 31(8):684–686.
27.
AsokanA, SchafferDV, SamulskiRJ. The AAV vector toolkit: Poised at the clinical crossroads. Mol Ther, 2012; 20(4):699–708.
28.
DryjaTP, HahnLB, CowleyGS, et al.Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A, 1991; 88(20): 9370–9374.
29.
DryjaTP, McGeeTL, HahnLB, et al.Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med, 1990; 323(19):1302–1307.
30.
SakamiS, MaedaT, BeretaG, et al.Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem, 2011; 286(12):10551–10567.
31.
SakamiS, KolesnikovAV, KefalovVJ, et al.P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. Hum Mol Genet, 2014; 23(7):1723–1741.
32.
WangH, YangH, ShivalilaCS, et al.One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell, 2013; 153(4):910–918.
33.
RichardsonCD, RayGJ, DeWittMA, et al.Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol, 2016; 34(3):339–344.
34.
LiuCH, WolfP, DongR, et al.A mutation-independent CRISPR/Cas9-based ‘Knockout and Replace’ strategy to treat rhodopsin-associated autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2022; 63(7):3474.
35.
YanWX, HunnewellP, AlfonseLE, et al.Functionally diverse type V CRISPR-Cas systems. Science, 2019; 363(6422):88–91.
36.
ZhangH, LiZ, XiaoR, et al.Mechanisms for target recognition and cleavage by the Cas12i RNA-guided endonuclease. Nat Struct Mol Biol,, 2020; 27(11):1069–1076.
37.
KleinstiverBP, TsaiSQ, PrewMS, et al.Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol, 2016; 34(8):869–874.
38.
McGawC, GarrityAJ, MunozGZ, et al.Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing. Nat Commun, 2022; 13(1):2833.
39.
ZhangH, KongX, XueM, et al.An engineered xCas12i with high activity, high specificity, and broad PAM range. Protein Cell, 2023; 14(7):538–543.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
